Study | Outcomes assessed | Hazard ratio (95% CI) | Factors adjusted in multivariate analysis |
---|---|---|---|
Yeh 2020 [17] | Graft failure MACE All-cause mortality Death with functioning graft | 1.75 (1.56, 1.96) 1.59 (1.38, 1.84) 1.79 (1.59, 2.01) 1.94 (1.71, 2.20) | Age, gender, Charlson comorbidity scores, place of residence, income levels, occupations, presence of comorbidities (including malignancy, hypertension, hyperlipidemia, cerebrovascular disease, myocardial infarction, congestive heart failure, peripheral vascular disease, atrial fibrillation, chronic obstructive pulmonary disease, cirrhosis, hepatitis B virus, hepatitis C virus), cyclosporine, tacrolimus, mycophenolate mofetil, mammalian target of rapamycin inhibitor, steroid, kidney transplantation rejection and cytomegalovirus infection |
Aleksic 2020 [28] | All-cause mortality | 1.40 (0.23, 8.51) | Age, gender, and serum creatinine one year post-transplant |
Dienemann 2016 [16] | All-cause mortality Graft failure Death censored graft loss Death with functioning graft | 1.57 (1.16, 2.12) 1.22 (1.00, 1.48) 1.10 (0.87, 1.39) 1.44 (1.07, 1.95) | Age, gender, ethnicity, rejection in first year, hepatitis C virus + status, delayed allograft function, living donor, glomerulonephritis, cardiovascular disease before transplant, time on dialysis, transplant year, e-glomerular filtration rate at 6 months, donor age, body mass index, cold ischemia time, HLA-DR mismatch, Panel reactive antibody status, tacrolimus as starting agent and cytomegalovirus disease |
Lv 2014 [27] | All-cause mortality | 1.22 (0.80, 1.84) | Age, year of transplant, postoperative onset of tumor, postoperative infection, and other risk factors |
Wauters 2012 [15] | All-cause mortality | 3.48 (2.25, 5.38) | NR |
Valderhaug 2012 [29] | Graft failure | 1.30 (0.98, 1.73) | Age, gender, body mass index, creatinine level at baseline, deceased-donor status, preemptive trans- plantation, donor age, early rejection, and early cytomegalovirus infection |
Valderhaug 2011 [30] | All-cause mortality | 1.54 (1.09, 2.17) | Age, gender, body mass index, creatinine, pre-transplant cardiovascular disease, total cholesterol, hypertension, and smoking status, donor status, pre-emptive transplantation, cytomegalovirus infection, early rejection, and use of cyclosporine A |
Tsai 2011 [31] | All-cause mortality Graft failure | 0.63 (0.13, 2.97) 0.44 (0.05, 3.73) | Age, gender, parental diabetes mellitus, hepatitis C virus, duration of renal replacement therapy, cardiovascular accident, coronary artery disease, peripheral artery occlusive disease, and hypertension |
Kuo 2010 [32] | All-cause mortality Graft failure Death censored graft loss | 1.22 (0.94, 1.59) 1.20 (0.99, 1.47) 1.16 (0.89, 1.50) | Age, sex, race, body mass index, primary payment, pretransplant comorbid conditions (hypertension, cardiovascular disease, peripheral vascular disease, and hepatitis C infection), duration of pretransplant dialysis therapy, serum creatinine level at 1 year, peak panel-reactive antibody titer, expanded criteria donor, HLA mismatch, induction therapy, immunosuppression at discharge, cold ischemia time (deceased donor only), and living/deceased donor |
Demirci 2010 [23] | Graft failure | 1.49 (1.05, 2.10) | Age, gender, acute rejection, pre-transplant dialysis duration, hepatitis C infection, cytomegalovirus infection |
Cole 2008 [18] | Graft failure Death censored graft loss Death with functioning graft | 1.24 (1.14, 1.35) 1.12 (0.99, 1.26) 1.41 (1.25, 1.59) | Patient demographics (age at transplantation, gender, race, cause of end stage renal disease, duration of dialysis before transplantation, body mass index, hepatitis C sero-status) and transplant characteristics (donor source, HLA mismatch, panel reactive antibody, transplant era, induction immunosuppression, and maintenance immunosuppression [medications prescribed at the time of hospital discharge after transplantation]) |
Gonzalez-Posada 2006 [24] | All-cause mortality Death censored graft loss | 1.55 (1.05, 2.27) 1.02 (0.71, 1.48) | NR |
Kasiske 2003 [25] | All-cause mortality | 1.87 (1.60, 2.18) | Age, race, ethnicity, donor gender, HLA mismatch, obesity, hepatitis C, education, immunosuppression, cause of disease, transplant year, donor source (living vs. cadaver), preemptive transplantation, gender, employability, donor age, donor race, cold ischemia time, panel reactive antibody status, and other immunosuppressive agents |
Cosio 2002 [26] | All-cause mortality | 1.88 (1.07, 3.30) | Age, gender; serum albumin, weight, total cholesterol, triglycerides, systolic blood pressure |